EFFICACY AND SAFETY OF TRIPLE THERAPY WITH PEGINTERFERON, RIBAVIRIN, AND BOCEPREVIR WITHIN EARLY ACCESS PROGRAM IN SPANISH PATIENTS WITH HEPATITIS C GENOTYPE 1 WITH SEVERE FIBROSIS: SVRW12 ANALISYS

被引：0
|
作者：
Calleja, J. L.
Ruiz, B.
Pascasio, J. M.
Gea, F.
Barcena, R. [1 ]
Larrubia, J. R. [2 ]
Forns, X.
Alvarez, R.
Sola, R.
Romero, M.
Sancho, A.
Salcedo, I.
Fernandez, M. J.
机构：
[1] Univ Hosp Ramon & Cajal, Madrid, Spain
[2] Univ Hosp Guadalajara, Guadalajara, Jalisco, Mexico
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2013年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：32 / 33
页数：2
相关论文
共 50 条
  • [21] Treatment Of Hepatitis C Genotype 1 Patients With Severe Fibrosis Or Compensated Cirrhosis: Efficacy Results To Week 16 On 1587 Patients From The International Telaprevir Early Access Program
    Abrao Ferreira, Paulo R.
    Colombo, Massimo
    Urbanek, Petr
    Strasser, Simone I.
    Moreno, Christophe
    Fernandez, Inmaculada
    Abdurakhmanov, Djamal
    Streinu-Cercel, Adrian
    Gaeta, Giovanni B.
    Verheyen, Anke
    Iraqi, Wafae
    DeMasi, Ralph
    Hill, Andrew
    Laeuffer, Joerg M.
    Lonjon-Domanec, Isabelle
    Wedemeyer, Heiner
    HEPATOLOGY, 2013, 58 : 1108A - 1109A
  • [22] Safety and efficacy of triple therapy containing boceprevir (BOC) or telaprevir (TVR) plus peginterferon alfa-2a / ribavirin in patients with advanced fibrosis or cirrhosis in real-life setting
    Mauss, Stefan
    Schober, Andreas
    John, Christine
    Lutz, Thomas
    Moog, Gero
    Bruch, Harald-Robert
    Teuber, Gerlinde
    Christensen, Stefan
    Heyne, Renate
    Pape, Stefan
    Naumann, Uwe
    Roessle, Martin
    Schiffelholz, Willi
    Loehr, Hanns-Friedrich F.
    Alshuth, Ulrich
    Hueppe, Dietrich
    HEPATOLOGY, 2013, 58 : 1098A - 1099A
  • [23] Treatment of hepatitis c genotype 1 patients with severe fibrosis or compensated cirrhosis: The telaprevir early access program in patients from Australia and New Zealand
    Macdonald, G. A.
    Roberts, S. K.
    Dore, G. J.
    Gane, E. J.
    Thompson, A. J.
    Weltman, M. D.
    Weilert, F.
    Hill, A.
    Laeuffer, J.
    Strasser, S. I.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 169 - 169
  • [24] Efficacy of Boceprevir Based Triple Therapy in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) Under Real Life Conditions in Treatment Experienced Patients Infected With Chronic Hepatitis C, Genotype 1: The PAN Study
    Moog, Gero
    Mauss, Stefan
    Hueppe, Dietrich
    Spengler, Ulrich
    Schott, Eckart
    Eisenbach, Christoph
    Schober, Andreas
    Heyne, Renate
    Jung, Maria-Christina
    Teuber, Gerlinde
    Doss, Margareta Frank
    Roessle, Martin
    Pape, Stefan
    Schuchmann, Marcus
    Alshuth, Ulrich
    Buggisch, Peter
    GASTROENTEROLOGY, 2013, 144 (05) : S982 - S982
  • [25] Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection
    Perello, C.
    Carrion, J. A.
    Ruiz-Antoran, B.
    Crespo, J.
    Turnes, J.
    Llaneras, J.
    Lens, S.
    Delgado, M.
    Garcia-Samaniego, J.
    Garcia-Paredes, F.
    Fernandez, I.
    Morillas, R. M.
    Rincon, D.
    Porres, J. C.
    Prieto, M.
    Lazaro Rios, M.
    Fernandez-Rodriguez, C.
    Hermo, J. A.
    Rodriguez, M.
    Herrero, J. I.
    Ruiz, P.
    Fernandez, J. R.
    Macias, M.
    Pascasio, J. M.
    Moreno, J. M.
    Serra, M. A.
    Arenas, J.
    Real, Y.
    Jorquera, F.
    Calleja, J. L.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (03) : 226 - 237
  • [26] Efficacy and safety of peginterferon alfa-2a administrated every five days in combination with ribavirin in HCV genotype 1-infected patients with severe fibrosis not responding to weekly administrations of PEGinterferon in combination with ribavirin
    Hezode, Christophe
    Bouvier-Alias, Magali
    Roudot-Thoraval, Francoise
    Zafrani, Elie-Serge
    Dhumeaux, Daniel
    Mallat, Ariane
    Pawlotsky, Jean-Michel
    HEPATOLOGY, 2006, 44 (04) : 322A - 322A
  • [27] Outcome in Partial Early Virologic Responders to Combination Therapy With Peginterferon and Ribavirin in Patients Infected With Hepatitis C Virus Genotype 1b
    Toyoda, Hidenori
    Kumada, Takashi
    Kiriyarna, Seiki
    Tanikawa, Makoto
    Hisanaga, Yasuhiro
    Kanamori, Akira
    Tada, Toshifumi
    Hosokawa, Takanori
    Arakawa, Takahiro
    Fujimori, Masashi
    JOURNAL OF MEDICAL VIROLOGY, 2011, 83 (01) : 101 - 107
  • [28] High predictive value of early viral kinetics in peginterferon plus ribavirin combination therapy of genotype 1 infected patients with chronic hepatitis C
    Oze, Tsugiko
    Hiramatsu, Naoki
    Inoue, Yuko
    Kurashige, Nao
    Kurokawa, Mika
    Yokushijin, Takayuki
    Igura, Takumi
    Imanaka, Kazuho
    Oshita, Masahide
    Hagiwara, Hideki
    Mita, Eiji
    Ito, Toshifumi
    Hijioka, Taizo
    Yoshihara, Harumaso
    Imai, Yosuharu
    Hayashi, Eijirou
    Kato, Michio
    Minami, Yuzo
    Ohkawa, Kazuyoshi
    Kiso, Shinichi
    Kanto, Tatsuya
    Takehara, Tetsuo
    Kasahara, Akinori
    Tamura, Shinji
    Hayashi, Norio
    HEPATOLOGY, 2007, 46 (04) : 376A - 377A
  • [29] Early Viral Response Predicts the Efficacy of Antiviral Triple Therapy with Simeprevir, Peg-Interferon and Ribavirin in Patients Infected with Hepatitis C Virus Genotype 1
    Nishida, Naoshi
    Iwanishi, Mina
    Minami, Tomohiro
    Chishina, Hirokazu
    Arizumi, Tadaaki
    Takita, Masahiro
    Kitai, Satoshi
    Yada, Norihisa
    Ida, Hiroshi
    Hagiwara, Satoru
    Minami, Yasunori
    Ueshima, Kazuomi
    Sakurai, Toshiharu
    Kitano, Masayuki
    Kudo, Masatoshi
    DIGESTIVE DISEASES, 2015, 33 (06) : 708 - 714
  • [30] Efficacy and Safety of Telaprevir, Pegylated Interferon α-2b and Ribavirin Triple Therapy in Japanese Patients Infected with Hepatitis C Virus Genotype 1b
    Kawaguchi, Yasunori
    Iwane, Shinji
    Kumagai, Takanori
    Yanagita, Kimihiko
    Yasutake, Tsutomu
    Ide, Yasushi
    Otsuka, Taiga
    Eguchi, Yuichiro
    Ozaki, Iwata
    Akiyama, Takumi
    Kawazoe, Seiji
    Mizuta, Toshihiko
    INTERNAL MEDICINE, 2015, 54 (20) : 2551 - 2560
12345